Two companies from the Science Park Park, Action Genes Inc. and Lung Cancer Diagnostics Expert Sunmi Co., Ltd. announced their merger today. The two companies described the merger as adding a comprehensive cancer diagnostic base in Asia, demonstrating the medical technology of Hong Kong and the Greater Bay Area. potential.
Dr. Chen Huajian, CEO of Action Gene, said that the merger will significantly broaden the vision of both parties in terms of product supply, business strategy and future vision.
The merged group will be able to more effectively use the respective leadership advantages of both parties to form a new generation of tumor diagnosis base, while investing in environmental, social and governance work in Asia.
Mo Shujin, Chairman of Sunmi Co., Ltd. said that Sunmi is very happy to join the mobile gene family. The team is ready to use professional skills and knowledge to contribute to the expanded Jiguo, especially in the areas of lung cancer and first-hand clinical experience. Assist clinicians to provide more comprehensive programs and services.
This merger will also allow us to reach more patients and pharmaceutical companies in other regions.
Four wholly-owned laboratories and two in Hong Kong
After the merger, the group will have four wholly-owned laboratories, two in Hong Kong, one in Taipei and one in Bangkok.
Among them, the three laboratories in Hong Kong and Taipei have obtained the authoritative certification of the American College of Pathologists (CAP).
In addition, the group’s joint venture with Canon Medical Systems also owns a CAP-certified laboratory in Kanagawa, Japan, and another newly established laboratory in Taipei by a joint venture with Cerba Research, focusing on immunohistochemistry and flow cytometry. Cytology research.
The expanded company has offices in Hong Kong, Taipei, Tokyo, Singapore, Bangkok and Wales (UK).
Further utilize its synergistic advantages to provide services to the medical and drug-delivery communities in Asia and Europe.
Interview | Two leading cancer genetic testing leaders merged with Mo Shujin: The amount of testing doubled in order to reduce costs. Gastric cancer is the sixth largest cancer killer in Hong Kong. The risk of gastric cancer increases without a fixed time. Doctors call for gastroscopy to screen 5,575 new lung cancer cases in 2019. More than 50% of patients have gene mutations, Professor Mo Shujin of the University of China, who has studied the treatment of lung cancer, is known as the ``2020 Oncology Giant''.
